domingo, 17 de noviembre de 2013

PLOS Biology: Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate

PLOS Biology: Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate

Genomic Screening of Healthy Individuals? Not Ready for Practice



Perspective

Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate

  • Timothy Caulfield mail,

  • Jim Evans,
  • Amy McGuire,
  • Christopher McCabe,
  • Tania Bubela,
  • Robert Cook-Deegan,
  • Jennifer Fishman,
  • Stuart Hogarth,
  • Fiona A. Miller,
  • Vardit Ravitsky,
  • Barbara Biesecker,
  • Pascal Borry,
  • Mildred K. Cho,
  •  [ ... ],
  • Brenda Wilson
  • , [ view all ]
  • Published: Nov 05, 2013
  • DOI: 10.1371/journal.pbio.1001699

Summary

The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.

No hay comentarios: